



AMGEN MISSION
To serve patients

AMGEN KOREA QUICK FACTS

Leadership

Sang Noh
General Manager

Staff

167 in Korea
(as of February 2023)

R&D Expense

Approximately \$4.8 billion
(as of 2021, Amgen Global
Headquarters)

Products

Repatha® (evolocumab)
BLINCYTO® (blinatumomab)
XGEVA® (denosumab)
EVENTITY® (romosozumab-aqqg)
KYPROLIS® (carfilzomib)
Prolia® (denosumab)
LUMAKRAS® (sotorasib)

Address/Phone

Amgen Korea 20 FL,
Ferrum Tower, 19
Eulji-ro 5-gil, Jung-gu, Seoul
(82) 2-3434-4800

About Amgen Korea

Our Mission: To Serve Patients

Amgen, founded in 1980 in Thousand Oaks, California, US has grown to be one of the world's leading biotechnology companies by unlocking the potential of biology into innovative human therapeutics. As a biotechnology leader, Amgen focuses on areas of high unmet medical needs and leverages advanced human genetics to unravel the complexities of disease, develop an innovative pipeline of transformative new medicines, and reach millions of patients around the world.

Amgen opened an affiliate in Korea in November, 2015, to market its innovative bio medicines for Korean patients under the mission of "To Serve Patients" in therapeutic areas of bone disease, cardiovascular, and oncology. Amgen Korea is committed to playing an active role in biotechnology and thereby helping to advance the growth of the local pharmaceutical industry.

OUR BIOTECHNOLOGIES ENABLE US TO OFFER INNOVATIVE CLINICAL BENEFIT FOR LOCAL PATIENTS

Amgen Korea provides transformative medicines powered by its expertise in biotechnology to give alternative treatment options with breakaway potential to local patients suffering from serious illnesses.

Innovative therapies from Amgen, all powered and enabled by Amgen's expertise in biotechnology, have become available in Korea starting from KYPROLIS® (carfilzomib) for multiple myeloma in April 2016, followed by BLINCYTO® (blinatumomab), Prolia® (denosumab), XGEVA® (denosumab), Repatha® (evolocumab), and EVENTITY® (romosozumab-aqqg).

Global Headquarters
Thousand Oaks, California, USA

FOR MORE INFORMATION ON
AMGEN KOREA, PLEASE VISIT
WWW.AMGEN.CO.KR

FOR MORE INFORMATION ON
AMGEN INC., PLEASE VISIT
WWW.AMGEN.COM

And in 2022, LUMAKRAS® (sotorasib) was approved as the first targeted therapy for KRAS G12C-mutated non-small cell lung cancer (NSCLC) in Korea. We are also dedicated to improved access to care for more patients in Korea to quickly receive life-changing therapeutic benefits of our products.

On the back of its broad pipeline of new medicines in clinical development, Amgen Korea strives to deliver innovative new medicines to local patients faster in such therapeutic areas as solid tumor and hematologic malignancies.

Products of Amgen Korea

Prolia®	Postmenopausal women/men with osteoporosis Glucocorticoid-induced osteoporosis Bone loss in patients with prostate/breast cancer
XGEVA®	Reduction of the risk for developing skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. Giant cell tumor of bone
BLINCYTO®	MRD-positive B-cell Precursor ALL Relapsed or Refractory B cell Precursor ALL
KYPROLIS®	Relapsed or refractory multiple myeloma
Repatha®	Hypercholesterolemia and mixed dyslipidemia Homozygous Familial Hypercholesterolemia Atherosclerotic cardiovascular disease
EVENITY®	Osteoporosis in postmenopausal women/men at high risk of fracture
LUMAKRAS®	Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior therapy

WE GIVE THE SOLUTION AS A BIOTECHNOLOGY LEADER WITH CONTINUOUS INVESTMENT IN R&D

A leading innovator in biotechnology since 1980, Amgen has cultivated and accumulated R&D expertise in multiple treatment modalities – large molecule proteins, small molecules, and antibodies – allowing us to choose and capitalize on the best target for attacking disease. Amgen focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. Amgen is continuously investing in new drug discovery research efforts to further advance our pipeline and clinical asset.

Amgen Korea has been relentless in making an investment in clinical trials in Korea for the past 12 years (as of June 2022) in such diverse areas as cardiovascular disease, oncology, bone disease, neuroscience, nephrology, and inflammation. We have had 71 clinical trials with 564 clinical trial sites and 6,972 patients in Korea being involved in the clinical trials led by Amgen. The investment is to demonstrate that our innovative medicines in development can offer clear clinical benefit and value to local patients as well, showcasing our effort to help more local patients be benefitted from our transformative products in line with Amgen’s mission of “To Serve Patients”.

Amgen Korea has in place a variety of open innovation programs in partnership with the Korea Health Industry Development Institute (KHIDI) designed to discover and foster promising biopharmaceutical companies in Korea, such as Amgen Science Academy Bioday to introduce science and technologies under development at Amgen and give networking opportunities, and Amgen Science Academy Pitching Day to select companies equipped with breakthrough technologies and capabilities to grant them prize money as well as mentoring opportunities from global R&D experts at Amgen.



AMGEN KOREA HISTORY

2015

- Amgen's Korean affiliate opens
- Sang Kyung Noh takes office as GM
- MoFDS approves BLINCYTO®
- MoFDS approves KYPROLIS**

2016

- BLINCYTO® becomes reimbursable

2017

- Repatha® is approved
- Prolia® becomes reimbursable

2018

- Amgen Science Camp, as a CSR initiative for underprivileged children, is held
- KYPROLIS® becomes reimbursable
- Repatha® becomes reimbursable
- XGEVA® becomes reimbursable

2019

- EVENITY® is approved
- Amgen Korea is selected as Korea Exemplary Workplace by MoEL
- Amgen Korea office moves to Ferrum Tower in Eulji-ro

2020

- EVENITY® becomes reimbursable
- An MOU with the Seoul Science Center is signed for the Grow up, Bio up campaign
- Amgen Korea is awarded the Seoul Council on Social Welfare Chairman's Certificate of Recognition in celebration of the 3rd Social Contribution Week hosted by the City of Seoul and Seoul Council on Social Welfare
- Amgen Korea is awarded the Order of the Red Cross, Member medal in Class 4 by the Korean Red Cross

2021

- An MOU with the Korean Academy of Science and Technology is signed for the Amgen-KAST Biotechnology Award
- An MOU with the Jung-gu, one of districts in Seoul metropolitan government, and Community Chest of Korea is signed for the Golden House Bone Health campaign
- Amgen Science Academy Bioday is hosted with the Korea Health Industry Development Institute

* Marketing approval as an orphan drug was granted in November 2015 and the orphan drug designation was lifted in March 2017, after which new drug approval was granted

Amgen Korea, as a biotechnology leader, will continue to invest in broad research programs, talent development, and organizational growth to encourage mutual growth with the local healthcare industry equipped with excellent researchers and infrastructure.

DRIVEN BY ESG GOALS ROOTED IN OUR MISSION OF "TO SERVE PATIENTS", WE ARE COMMITTED TO BUILDING TRUST AND MAKING THE WORLD A BETTER PLACE

Guided by Amgen global ESG (Environmental, Social, Governance) aspirations, Amgen Korea operates under the goal of shared growth of our business and the Korean society together, which is well-reflected in business strategies and activities we have launched on many fronts to be a socially responsible company.

For Social topics, the Corporate Responsibility 2025 Plan has been in place that incorporates a variety of community outreach programs designed to help make the Korean society that Amgen Korea serves a better place and increase investment in the local communities by leveraging our business influence in the relevant sectors. Our Corporate Responsibility 2025 Plan, as we are a leading biotechnology company with proven expertise, consists of activities aiming at identifying and supporting promising scientists in life science in different stages of lifecycle and programs that can bring about immediate impact on the communities. Programs under the plan include the Grow up, Bio up Campaign with the Seoul Science Center for life science education of children and adolescents; the Amgen-KAST Biotechnology Awards with the Korean Academy of Science and Technology to support young promising scientific minds in life science; the Blue Wish Campaign with Make-A-Wish Korea to grant a wish for children with critical illnesses; and the Golden House Bone Health Campaign with Jung-gu, one of the districts in the Seoul metropolitan government, and the Community Chest of Korea to improve residential conditions for vulnerable seniors in the community. Amgen Korea's efforts to be socially responsible in 2022 and 2023 were recognized as it was inducted into the Jung-gu Hall of Fame, a prestige given to exemplary donors or sponsors.

In the thick of the COVID-19 pandemic in 2020, Amgen Korea lent a helping hand jointly with Amgen Global to those marginalized by the pandemic, with the Korean Red Cross and Seoul Council on Social Welfare, as part of the public health and livelihood support programs. Our resolve to help the less privileged was appreciated when we were awarded the Seoul Council on Social Welfare Chairman's Certificate of Recognition in celebration of the 3rd Social Contribution Week by the City of Seoul, and the Order of the Red Cross, Member medal in Class 4 by the Korean Red Cross.

As for Environmental topics, in conjunction with the Amgen's 2027 Environmental Sustainability Plan, Amgen Korea Green Drive Program was launched to support 100% carbon neutrality for employees, with other hands-on environmental sustainability projects also in place such as making and donation of solar lanterns by employees and making environment-themed educational material for children.



2022

- MoFDS approves LUMAKRAS®
- An MOU with Make-A-Wish Korea is signed for the Blue Wish campaign
- Green Drive Program is launched for carbon neutrality
- The Ministry of Gender Equality and Family grants the “Family-friendly Company” Certificate

2023

- Amgen Korea is inducted into the Jung-gu Hall of Fame for being an exemplary donor in the community.



Governance topics are brought to life in the working environment at Amgen Korea where diversity, inclusion and belonging are promoted so that people at Amgen Korea can grow and prosper while achieving a good work-life balance. Examples include Employee Consultative Group by which employees participate in designing and implementing relevant programs that can accelerate improvements in work efficiency, corporate culture and working environment; and the Work Empowered Program for planning out works regardless of time and location. Also, in place are WE2 for networking between female employees to inspire and foster women’s leadership; the internal mentorship program for employees’ career and capability development; and the work-exchange program allowing employees to experience what other departments are doing. Our efforts, both internal and external, were acknowledged and we were named “2019 Korea Exemplary Workplace” by the Ministry of Employment and Labor, and “Family-friendly Company” by the Ministry of Gender Equality and Family in 2022.

[Appendix] Amgen Korea: ESG (Environmental, Social, Governance) Framework

